CTOs on the Move

Rocket Pharmaceuticals

www.rocketpharma.com

 
Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company advancing numerous gene therapies that could cure rare childhood diseases. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for seeking gene therapy cures for devastating diseases and making a difference for patients. Become an integral part of a small, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kinnari Patel
President, Head of Research & Development and Chief Operating Officer Profile
Chris Stevens
Chief Operating Officer Profile
Chantal Petit
VP, Chief of Staff supporting the President/Head R&D/COO at Rocket Pharmaceuticals Profile
Mayo Pujols
Executive Vice President and Chief Technical Officer Profile

Similar Companies

Therapure

Therapure is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Walter Payton Cancer Fund

Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

xbiotech usa inc

xbiotech usa inc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FLX Bio

FLX Bio, Inc. is a biotechnology company focused on the discovery and development of novel therapies that will improve and prolong the lives of people with cancer. The company is targeting key cancer pathways with its clinical-stage program, FLX925, and building a pipeline of immuno-oncology oral medicines designed to activate a patient`s own immune system to eradicate cancer.

Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.